Edison, NJ, United States of America

Prem Sagar Akasapu

USPTO Granted Patents = 26 


 

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 85(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
Loading Chart...
26 patents (USPTO):Explore Patents

Title: Prem Sagar Akasapu: A Maverick in Pharmaceutical Innovations

Introduction:

Prem Sagar Akasapu, a brilliant inventor and innovator in the field of pharmaceuticals, has made significant contributions to the medical industry through his groundbreaking patents. With a stronghold in the heart of Edison, NJ, Akasapu has left an indelible mark with 22 patents to his name. This article explores his latest patents, career highlights, notable collaborations, and his invaluable contributions to the field of pharmaceuticals.

Latest Patents:

Akasapu's most recent patents showcase his expertise and dedication to improving drug administration and stability. Notable among them are:

1. Succinylcholine Prefilled Syringe, Compositions, and Methods:

This patent revolves around pre-filled glass syringes, pharmaceutical compositions, and kits designed to enable the emergency administration of drugs to patients via a needleless connector. These syringes, with a minimum drug volume of 5 mL and a Luer-lock mechanism, eliminate the risk of plastic materials leaching and degradation. They significantly enhance safety by ensuring proper attachment to an IV line through a needleless connector.

2. Atropine Pharmaceutical Compositions:

This patent focuses on the development of sterile and storage-stable low-dose atropine formulations. The compositions presented here are substantially preservative-free, exhibiting minimal tropic acid content (less than 0.35%). By reducing the reliance on preservatives, Akasapu's formulations create safer alternatives for medical practitioners and patients alike.

Career Highlights:

Prem Sagar Akasapu's illustrious career has seen him deliver exceptional contributions within notable pharmaceutical companies. He has worked with:

1. Nevakar Inc. (formerly NVK Pharmaceuticals Inc.):

Akasapu spearheaded various successful projects at Nevakar Inc., an innovative pharmaceutical company specializing in developing differentiated injectable products. His expertise in drug formulation and development played a pivotal role in the company's success.

2. Nevakar Injectables Inc.:

Within Nevakar Injectables Inc., Akasapu continued to push boundaries, contributing his inventive spirit to create groundbreaking pharmaceutical solutions. His collaborative efforts and dedication to innovation earned him recognition as a key player within the organization.

Collaborations:

Akasapu's realization of complex projects has often been the result of fruitful collaborations. Notable among his coworkers are:

1. Kumaresh Soppimath:

Soppimath's expertise in drug delivery systems and novel formulation approaches made him an ideal partner for Akasapu. Together, they worked on projects that aimed to revolutionize drug administration techniques, ultimately benefiting both medical professionals and patients.

2. Iouri V Ilitchev:

Ilitchev's extensive experience in the pharmaceutical industry complements Akasapu's inventive mindset. Their collaboration yielded innovations that enhance drug stability and create safer alternatives for patients in need.

Conclusion:

Prem Sagar Akasapu, with his relentless pursuit of excellence and dedication to pharmaceutical innovation, has made exceptional contributions. His patents in the development of pre-filled syringes and storage-stable atropine formulations showcase his commitment to advancing medical practices. Collaborations with seasoned professionals further highlight his expertise and collaborative spirit. Moving forward, Akasapu's endeavors are bound to continue transforming the medical landscape and improving healthcare outcomes for the greater good.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…